BUZ INVESTORS PRESS RELEASE Cannabis Oils Aurora Cannabis Inc. (the "Company" or "Aurora") (TSX-V: ACB) (OTCQX: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) today announced that the Company has commenced sales of a new product line

Aurora Commences Sales of Cannabis Oils

Chart | Calendar   | TRADE NOW | Aurora Cannabis

Aurora Commences Sales of Cannabis Oils

 BUZ INVESTORS PRESS RELEASE Cannabis Oils Aurora Cannabis Inc. (the "Company" or "Aurora") (TSX-V: ACB) (OTCQX: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) today announced that the Company has commenced sales of a new product line

 BUZ INVESTORS PRESS RELEASE  Cannabis Oils Aurora Cannabis Inc. (the “Company” or “Aurora”) (TSX-V: ACB) (OTCQX: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) today announced that the Company has commenced sales of a new product line of ingestible cannabis oils called Aurora Drops.

The Company’s newest offerings include three distinct product types all priced equally at a standard flat rate of $115 per bottle, or $80 per bottle for clients approved for Aurora’s compassionate pricing program:

  1. THC Drops (Sativa) – a high potency THC oil extracted from Cannabis Sativa flowers
  2. THC Drops (Indica) – a high potency THC oil extracted from Cannabis Indica flowers
  3. CBD Drops – a high potency oil extracted from Aurora’s flagship CBD strain Temple (Cannatonic)

The Company’s ingestible cannabis oils come in 30 ml glass bottles with a child resistant certified cap and dropper to allow for the easy and accurate dosing of small amounts of the high potency fluids, and are produced using CGMP compliant supercritical CO2extraction technology, as well as using an MCT carrier oil sourced from coconut oil.



Cannabis Oils

>>>TRADE NOW<<<

As with all of Aurora’s cannabis products, the test results from the independent third-party lab for each batch of ingestible oil are publicly available. Test results can be accessed online at auroramj.com/strains, or through the Aurora Mobile app, a feature rich mobile experience for iOs and Android that displays inventory tracking and restocking events, and sends push notifications for new product releases.

“The launch of our first ingestible oil products represents a major milestone, which promises to add significantly to Aurora’s top and bottom line results,” said Neil Belot, Chief Global Business Development Officer.  “We have produced a sizeable inventory of Aurora Drops for our domestic medical client base, and will be continuing to ramp up production in order to address the strong demand we anticipate for high-quality, high-margin derivative products, manufactured under the rigorous Aurora Standards regarding processes, testing, and transparency.”

The Company recently signed a Memorandum of Understanding with Radient Technologies Inc. (“RTI”) with regards to the joint development and commercialization in Canada of superior and standardized cannabinoid extracts produced using RTI’s high-throughput, terpene-preserving, proprietary extraction technology.

“The strategic partnership with RTI has the potential to be a game changer in this high-margin, high-growth segment of the cannabis market, “said Terry Booth, CEO. “If the technology works as we anticipate, Aurora will be able to produce high volumes of terpene-rich cannabis derivatives at lower costs and much shorter harvest-to-market times than any company using current industry benchmark technologies. This would give us an even stronger competitive advantage in what may well become the dominant market segment. The launch of sales is the first step in establishing our brand in the derivatives market, and we are very pleased that we are able to expand our offering to a customer base looking for alternative methods to consume cannabis.”

The companies’ technical feasibility and commercial opportunities study currently underway is proceeding well, and is expected to be completed soon.

About Aurora

Aurora’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta,  is currently constructing a second 800,000 square foot production facility, known as “Aurora Sky”, at the Edmonton International Airport, and has acquired and is undertaking completion of a third 40,000 square foot production facility in Pointe Claire, Quebec, near Montreal. In addition, the company is the cornerstone investor with a 19.9% stake in Cann Group Limited, the first Australian company licensed to conduct research on and cultivate medical cannabis. Aurora’s common shares trade on the TSX-V under the symbol “ACB”.

On behalf of the Board of Directors,
AURORA CANNABIS INC.
Terry Booth, CEO

These comments contain certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

The TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Aurora Cannabis Inc.

Like up on FACEBOOK


Ebates Coupons and Cash Back



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




Buz Investors CMED, receives export permits CanniMed Therapeutics Inc. (“CanniMed” or the “Company”) (TSX: CMED) today announced the receipt, through its wholly-owned subsidiary Prairie Plant Systems Inc., of

CanniMed Cannabis Oils Facility Expansion with Support of the Saskatchewan Provincial Government

CanniMed Therapeutics Inc. Commences Cannabis Oils Facility Expansion with Support of the Saskatchewan Provincial Government

 

 

BUZ INVESTORS CanniMed Cannabis Oils Facility Expansion CanniMed Therapeutics Inc. (TSX: CMED) (“CanniMed” or the “Company”) announced today that its directors have approved

BUZ INVESTORS  CanniMed Cannabis Oils Facility Expansion CanniMed Therapeutics Inc. (TSX: CMED) (“CanniMed” or the “Company”) announced today that its directors have approved the commencement of a capital project to increase its current cannabinoid oils processing capacity by constructing a new facility on the Company’s Saskatchewan campus.

The planned Good Manufacturing Practice (GMP)-compliant ethanol extraction facility will have the initial capacity to supply the equivalent of 12 million 60 ml bottles of CanniMed® Oil per year, once complete. The initial cost estimate for the facility is $10.5 million over a twenty-month schedule to commissioning.

“Saskatchewan’s heritage of pioneering and innovation in Canadian healthcare has helped lead to the creation of cornerstones such as the advent of cobalt therapy in cancer treatment,” said Premier Brad Wall.  “CanniMed is now part of the ongoing legacy that embodies this spirit of creative thinking and diversification so inherent in our province.  We welcome this kind of significant investment in Saskatchewan.”



 CanniMed Cannabis Oils Facility Expansion 

The project is estimated to employ 85 full-time employees during the construction phase and will create 25 new permanent full-time positions. Scheduling and costs will be further refined during the detailed design phase of the project. The facility has been designed to accommodate further modular increases in capacity in up to three subsequent phases, ensuring product development milestones will continue to be met over the long-term.

“The Company’s greatest growth driver is currently our CanniMed® Oils products, contributing to 46% of our overall sales during March 2017,” said Brent Zettl, President and CEO of CanniMed Therapeutics Inc. “The expansion of our oils processing capacity will ensure ample supply of cannabinoid-based raw materials for future product development and innovation, in addition to providing for the continued growth of currently marketed oil products, and our soon-to-be released gelcaps.”

CanniMed uses ethanol (food-grade alcohol) extraction for the purification of cannabinoids. This industry-leading process pumps ethanol through compressed cannabis flower material, extracting the THCA (delta-9-tetrahydrocannabiolic acid), CBDA (cannabidiolic acid) and other medicinal ingredients. The alcohol and excess water are then removed through evaporation, resulting in a pure cannabis resin that can be further developed into a number of products for patient consumption. The Company plans to recycle and reuse the ethanol employed in the process.

About CanniMed Therapeutics Inc.

The Company is a Canadian-based, international plant biopharmaceutical company and a leader in the Canadian medical cannabis industry, with 15 years of pharmaceutical cannabis cultivation experience, state-of-the-art, GMP-compliant production process and world class research and development platforms with a wide range of pharmaceutical-grade cannabis products. In addition, the Company has an active plant biotechnology research and product development program focused on the production of plant-based materials for pharmaceutical, agricultural and environmental applications.

CanniMed Ltd., through its subsidiaries, was the first producer to be licensed under the Marihuana for Medical Purposes Regulations, the predecessor to the current Access to Cannabis for Medical Purposes Regulations. It was the sole supplier to Health Canada under the former medical marijuana system for 13 years, and has been producing safe and consistent medical marijuana for thousands of Canadian patients, with no incident of product diversion or recalls.

Like up on FACEBOOK


Ebates Coupons and Cash Back



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )